BRIEF-Biotest says phase IIb study of tregalizumab did not meet primary endpoint
April 24, 2015 at 03:15 AM EDT
* Phase IIb study of Tregalizumab (BT-061) in moderate to severe rheumatoide arthritis did not meet the primary endpoint - potential one time effect of 30 million euros ($32.59 million)
